Figure 9.Diagram illustrating the pathway of our proposed hypothetical mechanism. DNMT3B reduces the levels of MMP3 and MMP9 and increases the levels of collagen II and aggrecan through the TRPA1-COX2-YAP axis. DNMT3B then reduces the ECM degradation of NP cells and the inflammatory response, thereby alleviating IVDD.
